Drugs / LY4152199
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07101328 | May 2026 → Apr 2027 expected | Waldenstrom macroglobulinemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4152199 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07101328 ↗ |
| Route | Intravenous | “Administered by IV infusion” NCT07101328 ↗ |